VJHemOnc is committed to improving our service to you

COMy 2020 | Immunotherapy for treating multiple myeloma

VJHemOnc is committed to improving our service to you

Noopur Raje

Noopur Raje, MD, Massachusetts General Hospital, Boston, MA, discusses immunotherapeutic interventions to treat multiple myeloma. Dr Raje highlights allogeneic CAR T-cells that are currently in clinical trials. Belantamab mafodotin, an immunoconjugate targeting B-cell maturation antigen (BCMA), as used in the DREAMM trials (NCT04126200/NCT03525678), is now approved by the FDA and benefits patients for up to 3 months. Immunotherapies are off the shelf and easier than cell therapies. As both immunotherapies and cell therapies target the same antigen, which is BCMA, incorporating both therapies in the future could show benefit for multiple myeloma patients. Additionally, Dr Raje discusses Bispecific T-cell engager (BiTEs) antibodies, including teclistamab. This interview took place during the Controversies in Multiple Myeloma (COMy) 2020 Virtual World Congress.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter